KOSDAQ - Delayed Quote KRW
ORGANOIDSCIENCES (476040.KQ)
34,300.00
-2,200.00
(-6.03%)
As of 12:08:23 PM GMT+9. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Jong-Man Yoo | Chief Executive Officer | -- | -- | -- |
ORGANOIDSCIENCES
338 Pangyo-ro
6th floor Bundang-gu
Seongnam-si, 13488
South Korea
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.
Corporate Governance
ORGANOIDSCIENCES’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available